MedPath

Latanoprost

These highlights do not include all the information needed to use LATANOPROST OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for LATANOPROST OPHTHALMIC SOLUTION. LATANOPROST ophthalmic solution, 0.005%, for topical ophthalmic use Initial U.S. Approval: 1996

Approved
Approval ID

19cdfef0-b770-4758-8f59-1769e4b6119c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 11, 2023

Manufacturers
FDA

Aurobindo Pharma Limited

DUNS: 650082092

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Latanoprost

PRODUCT DETAILS

NDC Product Code65862-872
Application NumberANDA206519
Marketing CategoryC73584
Route of AdministrationOPHTHALMIC
Effective DateApril 11, 2023
Generic NameLatanoprost

INGREDIENTS (6)

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEInactive
Code: 593YOG76RN
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
LATANOPROSTActive
Quantity: 50 ug in 1 mL
Code: 6Z5B6HVF6O
Classification: ACTIB
SODIUM PHOSPHATE, DIBASIC, ANHYDROUSInactive
Code: 22ADO53M6F
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Latanoprost - FDA Drug Approval Details